Ad3-hTERT-E1A

AXP000072.1 · Oncolytic virus

Platform
adenovirus (serotype 3, hTERT promoter-driven E1A)
Originator
University of Helsinki (Akseli Hemminki)

Names

NameTypeSource
Ad3-hTERT-E1Apreferred name, codecurator, paper

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 3 (NCBI Taxonomy 45659)
Strain
Ad3
Replication
conditionally replicating
Modifications
hTERT promoter drives E1A
Route
intratumoral, intraperitoneal, intrapleural, intravenous
Source
evidence

Approvals

No regulatory approval recorded.

Clinical trials (0)

No trial in the latest ClinicalTrials.gov snapshot names this program.

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 22871667Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus, in patients with chemotherapy refractory cancer.Molecular therapy : the journal of the American Society of Gene Therapy2012name in title: Ad3-hTERT-E1A
PMID 21183947Oncolytic adenovirus based on serotype 3.Cancer gene therapy2011name in abstract: Ad3-hTERT-E1A

Notes

ATAP construct (2007-2012); a rare fully serotype-3 oncolytic adenovirus.

How to cite

Ad3-hTERT-E1A (AXP000072.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000072.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.